The global bioburden testing market size is expected to reach USD 3.22 billion by 2030, registering a CAGR of 14.3% during the forecast period. The market is expected to showcase upward trend in the forthcoming years owing to growing concerns about product safety. This has led to various government initiatives to promote microbiological safety testing tools.
A number of publications released by organizations to promote awareness regarding microbiological safety testing is broadening the future growth prospects of bioburden testing. For instance, the U.S. Department of Health and Human Services and Centers for Disease Control published Biosafety in Microbiological and Biomedical Laboratories (BMBL), which includes information pertaining to laboratory biosecurity and risk assessment, decontamination and sterilization, and biological toxins and biosafety levels in laboratories.
Growth of pharmaceutical, biotechnology, medical device, and food and beverage industries have contributed to the high growth of the bioburden testing market. In addition, increase in R&D investments by prominent companies is expected to encourage end users to adopt highly efficient bioburden testing tools to counter possible losses due to microbial contamination. Moreover, requirement for basic drug safety data requirements for preclinical studies is expected to fuel the demand for bioburden testing tools.
This product will be delivered within 1-3 business days.
A number of publications released by organizations to promote awareness regarding microbiological safety testing is broadening the future growth prospects of bioburden testing. For instance, the U.S. Department of Health and Human Services and Centers for Disease Control published Biosafety in Microbiological and Biomedical Laboratories (BMBL), which includes information pertaining to laboratory biosecurity and risk assessment, decontamination and sterilization, and biological toxins and biosafety levels in laboratories.
Growth of pharmaceutical, biotechnology, medical device, and food and beverage industries have contributed to the high growth of the bioburden testing market. In addition, increase in R&D investments by prominent companies is expected to encourage end users to adopt highly efficient bioburden testing tools to counter possible losses due to microbial contamination. Moreover, requirement for basic drug safety data requirements for preclinical studies is expected to fuel the demand for bioburden testing tools.
Bioburden Testing Market Report Highlights
- On the basis of product, consumables segment dominated the market in 2023 owing to a wide use of culture media and reagents and kits.
- The PCR instruments facilitate rapid analysis of bacterial bioburden, thus, fostering high market growth.
- The aerobic count-testing held largest market share in 2023 due to easy isolation of aerobic bacteria by culture media.
- Raw material testing is anticipated to showcase lucrative growth during the forecast period owing to the increasing number of product recalls and concern regarding product quality.
- On the basis of end-use, pharmaceutical and biotechnology companies dominated the market in 2023 owing to the high growth of this industry.
- The number of CMOs is increasing significantly, which has led to a rise in outsourcing services, thus, driving the segment growth.
- North America held the largest revenue share in 2023 due to high R&D spending by key companies and high healthcare spending in the U.S.
The leading players in the Bioburden Testing market include:
- Charles River Laboratories
- Merck KGaA
- SGS Société Générale de Surveillance SA.
- WuXi AppTec
- BD
- North American Science Associates, LLC
- Nelson Laboratories, LLC
- Thermo Fisher Scientific Inc
- BIOMÉRIEUX
- Pacific Biolabs
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Bioburden Testing Market Variables, Trends, & Scope
Chapter 4. Bioburden Testing Market: Product Estimates & Trend Analysis
Chapter 5. Bioburden Testing Market: Test Estimates & Trend Analysis
Chapter 6. Bioburden Testing Market: Application Estimates & Trend Analysis
Chapter 7. Bioburden Testing Market: End Use Estimates & Trend Analysis
Chapter 8. Bioburden Testing Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
Companies Mentioned
The leading players in the Bioburden Testing market include:- Charles River Laboratories
- Merck KGaA
- SGS Société Générale de Surveillance SA.
- WuXi AppTec
- BD
- North American Science Associates, LLC
- Nelson Laboratories, LLC
- Thermo Fisher Scientific Inc
- BIOMÉRIEUX
- Pacific Biolabs
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.28 Billion |
| Forecasted Market Value ( USD | $ 3.22 Billion |
| Compound Annual Growth Rate | 14.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
